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Summary 
An abnormal accumulation of cholesterol oxidation products in the brain of Alzheimer’s disease 
(AD) patients would further link an impaired cholesterol metabolism in the pathogenesis of the 
disease. The first evidence stemming from the content of oxysterols in autopsy samples from AD 
and normal brains points to an increase of both 27-hydroxycholesterol (27-OH) and 24-
hydroxycholesterol (24-OH) in the frontal cortex of AD brains, with a trend that appears related to 
the disease severity. The challenge of differentiated SK-N-BE human neuroblastoma cells with 
patho-physiologically relevant amounts of 27-OH and 24-OH showed that both oxysterols induce a 
net synthesis of A1-42 by up-regulating expression the levels of amyloid precursor protein and β-
secretase, as well as the β-secretase activity. Interestingly, cell pre-treatment with N-acetyl-cysteine 
(NAC) fully prevented the enhancement of β-amyloidogenesis induced by the two oxysterols. The 
reported findings link an impaired cholesterol oxidative metabolism to an excessive -
amyloidogenesis and point to NAC as an efficient inhibitor of oxysterols-induced A toxic peptide 
accumulation in the brain. 
 
Introduction 
Life expectancy has increased dramatically in most parts of the world over the last forty years but, 
in parallel, the impact of illness and disability on the aging population has also risen significantly. 
Alzheimer’s disease (AD) is undoubtedly one of the major age-related diseases, and its incidence 
continues increasing at an alarming rate. 
The underlying multifactorial and multistep disease process, characterized by brain 
accumulation of extracellular amyloid-β (Aβ) peptide plaques and intracellular neurofibrillary 
tangles, is often preceded and/or accompanied by other important morbidities, including abdominal 
obesity, insulin resistance, and altered cholesterol metabolism (Reitz, 2012; Gamba et al., 2012). 
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While the contribution made by altered brain cholesterol metabolism to the complex 
pathogenesis of AD has recently gained further consensus, the mechanisms linking this metabolic 
impairment to the hallmark lesions of AD, i.e. extracellular Aβ deposits and intraneuronal tau 
pathology, have not yet been clarified. 
To date, most research on this point has focused on the ability of cholesterol to modulate 
amyloidogenesis, i.e. Aβ production, in the brain. In this connection, experimental studies carried 
out thus far, using cell culture systems and/or animal models, have consistently proved that excess 
cholesterol may stimulate amyloidogenesis by neuronal cells, and that hypercholesterolemia is 
associated with increased deposition of Aβ in the brain (for a review see Ricciarelli et al., 2012). In 
one such study, a long-term dietary regimen rich in cholesterol not only augmented plasma 
cholesterol in rabbits, but also increased the cholesterol content in the animal’s neurons. In parallel, 
the level of neuronal β-secretase, the enzyme cleaving amyloid precursor protein (APP) so as to 
generate Aβ, was found to be increased, as was the level of Aβ itself (Ghribi et al., 2006). Rats fed a 
cholesterol-rich diet for 5 months showed impaired spatial memory, together with a significant loss 
of cholinergic neurons. These findings were associated with increased levels of APP, Aβ, and 
phosphorylated tau in the cerebral cortex. Importantly, this dietary regimen was demonstrated to 
derange the semi-permeability of the blood-brain barrier (Ehrlich & Humpel, 2012). 
Thus, at least in certain experimental animals, hypercholesterolemia may somehow favor an 
actual increase of neuron cholesterol content, one operated mechanism being modulation of the 
cellular processing of APP (Ghribi, 2008; Schweinzer et al., 2011). However, epidemiological 
studies relating high plasma cholesterol levels to AD, and clinical trials with hypocholesterolemic 
drugs, have thus far given controversial results (Reitz, 2012; Ricciarelli et al., 2012). 
Of note, whereas abnormalities in cholesterol metabolism are tied to a derangement of 
cholesterol synthesis and uptake in the peripheral tissues, leading to increased “total” plasma 
cholesterol, i.e. hypercholesterolemia, in many cases they also appear to involve oxidative 
modification of cholesterol and/or altered cholesterol homeostasis within the brain. As we know, 
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this compound is essential for brain structure and function and the cholesterol content of the brain 
accounts for about the 25% of the total body content (Björkhem & Meaney, 2004). In our view, the 
AD-predisposing role played by homozygosity for the apolipoprotein E (APOE) e4 allele (Evans et 
al., 2004) is likely just one of several ways in which abnormal brain cholesterol metabolism may 
contribute to the development of this disease. 
 A key role in the regulation of cholesterol homeostasis in the brain is undoubtedly played by 
the biochemical events that regulate its oxidation rate. In general, the production of cholesterol 
oxidation products in the body, particularly that of oxysterols, may be either enzymatic or non-
enzymatic (Leonarduzzi et al., 2002; Brown & Jessup, 2009; Sottero et al., 2009; Iuliano, 2011). In 
the brain, the enzymatic source of oxysterols greatly prevails, at least under physiological 
conditions; through this process the brain can release excess cerebral cholesterol into the blood 
stream. Whereas the normal blood brain barrier is not permeable to cholesterol as such, it thus 
allows the diffusion of at least some cholesterol oxidation products, for example 24-
hydroxycholesterol (24-OH) and 27-hydroxycholesterol (27-OH) (Björkhem et al., 2009). Mainly 
for this reason, scientists initially tended to consider oxidation of brain cholesterol as a beneficial 
event. However, it cannot be ruled out that, under pathological conditions like those leading to AD, 
steady-state levels of oxysterols in the brain may overwhelm the brain’s capacity to expel these 
compounds. In this connection, most oxysterols have shown 10-100 times stronger biochemical 
reactivity than the parent compound, often exhibiting quite strong pro-apoptotic and pro-
inflammatory effects (Poli et al., 2009; Vejux & Lizard, 2009). 
Significantly elevated levels of 24-OH have been found in the cerebrospinal fluid of AD 
patients (Schönknecht et al., 2002); levels of another oxysterol of enzymatic origin, 27-OH, were 
increased in the frontal cortex of AD patients versus control individuals, while the amount of frontal 
cortex 24-OH recovered in the same patients did not show any significant difference as to over 
controls (Heverin et al., 2004). The two enzymes catalyzing cholesterol oxidation into 24-OH or 
into 27-OH, respectively 24-cholesterol hydroxylase (CYP46) and 27-cholesterol hydroxylase 
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(CYP27), showed an abnormal pattern in the AD brain, with increased expression of 24-cholesterol 
hydroxylase in the neighborhood of amyloid plaques (Brown 3
rd
 et al., 2004). 
In the light of these findings, 24-OH and 27-OH have been the two main oxysterols 
considered over the last few years for their potential neurodegenerative action. However, to date 
few in vitro studies have focused on the possible implication of these two cholesterol oxidation 
products in amyloidogenesis. A significant up-regulation of the APP level (3.2 fold induction versus 
control cells) was observed in primary cultures of almost equal populations of human neuronal and 
glial cells, after incubation in the presence of 24-OH (10 µM final concentration) (Alexandrov et 
al., 2005). Following the treatment of the undifferentiated human neuroblastoma cell line SH-SY5Y 
with either 24-OH or 27-OH, both employed at 5 µM final concentration, a significant doubling of 
α-secretase and down-regulation of β-secretase (BACE1) activities occurred in the presence of 24-
OH, whereas 27-OH-treated cells behaved like controls (Famer et al., 2007). Another research 
group, adopting the same cell model system (SH-SY5Y), showed that 27-OH (5-15 µM final 
concentration) was significantly able to up-regulate cell APP levels and BACE1 activity, while 
identical concentrations of 24-OH did not show any significant effect either on APP levels or on 
BACE1 activity. The effect of the two oxysterols on α-secretase was not reported, but the 
possibility that 24-OH stimulated the non-amyloidogenic pathway was supported by a net increase 
of sAPPα secretion by SH-SY5Y treated with the latter compound (Prasanthi et al., 2009). 
 The present study comprises a comprehensive in vitro analysis of APP, α- β- and -secretase 
expression and levels, and β- and -secretase activities, all measured in a human neuroblastoma cell 
line (SK-N-BE); most important, the cells were first differentiated towards a neuronal phenotype, 
by treatment with all-trans-retinoic acid, then challenged with “patho-physiological amounts” of 
24-OH or 27-OH. The latter experimental condition was determined on the basis of the 
quantification of these two oxysterols in a few post-mortem samples of brains with different levels 
of Alzheimer pathology within a pilot analysis that might suggest their increasing trend in the AD 
brain frontal cortex with disease progression. Aβ production by differentiated SK-N-BE cells, under 
7 
 
treatment with 24-OH or 27-OH, was also investigated, as well as its potential modulation by cell 
pre-treatment with N-acetyl cysteine (NAC), a redox active molecule of clinical interest. 
 
Results 
Levels of 27-OH and 24-OH in the frontal cortex of AD brains: upward trend with disease 
progression 
A pilot study was done on autopsy samples of frontal cortex from AD brains partly in order to 
obtain reliable indications concerning the appropriate concentration of 27-OH and 24-OH to use in 
the in vitro experiments scheduled subsequently. As reported in Table 1, in control brain samples 
the average amounts of 27-OH and 24-OH recovered were about 0.2 and 2.5 ng/mg of tissue, 
respectively. Interestingly, when a distinction was made between early and advanced AD cases, 
following the classification of Braak and Braak (see Experimental procedures), the steady-state 
amounts of the two oxysterols recovered from the cerebral frontal cortex might increase with 
disease progression. When AD data were grouped together, not considering the disease stage of the 
donors, and compared to controls, frontal cortex 27-OH and 24-OH levels were respectively triple 
and double those of normal frontal cortex samples (Table 1). 
 Based on the amounts of 27-OH and 24-OH actually detected in AD and normal autopsy 
brains, given the molecular weight of 27-OH and 24-OH (M.W. 402.7 g/mol), the final 
concentration of 1 µM was deemed the most logical one to adopt for the in vitro analysis of 
amyloidogenesis in neuroblastoma-derived cells under challenge with oxysterols. 
 
27-OH and 24-OH up-regulate APP level in differentiated SK-N-BE human neuroblastoma 
cells 
The initial experiments, upon SK-N-BE differentiated into more neuron-like cells by treatment with 
all-trans-retinoic acid (see Experimental procedures), then incubated in the presence or absence of 
27-OH or 24-OH at the selected final concentration of 1 µM, verified the expression and level of 
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APP. Only 24-OH-treated cells showed statistically-significant over-expression of the amyloid 
precursor (Fig. 1A). Both oxysterols were in any case able to significantly increase the steady-state 
cellular concentration of APP protein (Fig. 1B). 
 
27-OH and 24-OH up-regulate BACE1 level in differentiated SK-N-BE cells 
As shown in Fig. 2A, 27-OH (1 µM final concentration) did not appear to significantly increase 
BACE1 mRNA levels, while treatment with the same concentration of 24-OH induced a 1.5-2 fold 
increase, which became statistically significant after 8-10 h cell incubation. However, both 
oxysterols up-regulated the secretase protein level. In fact, SK-N-BE treatment with 27-OH was 
followed by a statistically-significant increase in BACE1 protein levels (almost tripling them) after 
24 and 48 h cell incubation. In line with the mRNA results, 24-OH-challenged cells showed an 
earlier increase (3.5 fold) in BACE1 protein levels, which was already significant after 12 h 
incubation (Fig. 2B). 
 
27-OH, but not 24-OH, increases expression and synthesis of γ-secretase catalytic unit PS1 
To test the effect of the two oxysterols on γ-secretase, expression and protein levels of presenilin-1 
(PS1), i.e. the catalytic unit of γ-secretase, were determined. Real-time RT-PCR revealed that, in 
differentiated SK-N-BE neuroblastoma cells, a single treatment with 27-OH (1 µM) induced a 
statistically-significant increase (1.5 fold) in PS1 mRNA levels compared to untreated cells; 
conversely, cell treatment with 24-OH (1 µM) did not modify basal PS1 mRNA levels (Fig. 3A). 
PS1 protein level results were fully consistent with those obtained by real-time RT-PCR: 27-OH 
significantly increased the C-terminal fragment (CTF) of PS1 (CTF-PS1) levels (doubling them) in 
SK-N-BE cells, from 12 up to 48 h treatment, while 24-OH did not show any effect (Fig. 3B). 
 
27-OH and 24-OH up-regulate expression and synthesis of α-secretase 
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To evaluate the ability of 27-OH and 24-OH to modulate -secretase, we measured expression and 
protein levels of the main enzyme with -secretase activity in neurons, i.e. ADAM10 (a disintegrin 
and metalloproteinase domain-containing protein 10). ADAM10 mRNA levels in differentiated SK-
N-BE cells were found to be significantly increased by 1 M 27-OH and 24-OH, compared to 
untreated cells, with a maximum of 2 and 2.5 fold induction respectively (Fig. 4A). In addition, 
ADAM10 synthesis was markedly up-regulated (+50%) by both oxysterols from 12 up to 48 h 
treatment (Fig. 4B). 
 
Both 27-OH and 24-OH up-regulate BACE1 enzymatic activity; 27-OH also stimulates γ-
secretase enzymatic activity 
In a subsequent step, BACE1 and γ-secretase activities were quantified in differentiated SK-N-BE 
neuroblastoma cells challenged with a single dose of either 27-OH or 24-OH (1 µM). As shown in 
Fig. 5A, BACE1 activity was found to be significantly increased (+25%) in 27-OH-treated cells, but 
only after 48 h treatment; a statistically-significant increase of BACE1 activity was evident after 24 
h (+20%) and 48 hours (+40%) incubation with 24-OH. 
The results on γ-secretase activity paralleled those obtained by PS1 expression: γ-secretase 
activity was significantly increased in differentiated SK-N-BE cells after treatment with 27-OH 
(+20% after 24 h; +35% after 48 h). As expected, 24-OH did not modify γ-secretase activity (Fig. 
5B). 
 
27-OH and 24-OH markedly stimulate A1-42 production by differentiated SK-N-BE 
neuroblastoma cells 
In order to fully validate the observed stimulating effect of both 27-OH and 24-OH on APP 
processing, an ELISA kit procedure was used to quantify the intracellular concentration of Aβ1-42, 
the most toxic and fibrillogenic form of Aβ, before and after oxysterol challenge. Data reported in 
10 
 
Fig. 5C, clearly indicate that both oxysterols were able to induce a net increase in Aβ1-42 production 
by SK-N-BE cells; production was found to be about 3-4 times higher than in untreated cells. 
In an additional set of experiments, the effect of the oxysterol concentration used in this 
study (1 µM) was compared to the previously published ones (5 µM and 10 µM) with regard to 
Aβ1–42 production, the most critical point of the overall work, in both differentiated and non-
differentiated SK-N-BE cells (see Fig. S1, Supporting information). In differentiated cells, the 
ELISA quantification of Aβ1-42 confirmed that the treatment with 1 M 27-OH or 24-OH induced 
about a fourfold increase of the toxic peptide production, while higher concentrations of the 
oxysterols (5 and 10 M) did not show any statistically-significant effect. In undifferentiated cells, 
only the treatment with 5 M 27-OH showed a statistically-significant but moderate increase 
(+50%) of Aβ1-42; conversely, 1 M 27-OH, 1 and 5 M 24-OH did not affect the Aβ constitutive 
amount which is relatively lower than that found in differentiated control cells. At the higher 
oxysterol concentration tested (10 M), the amounts of Aβ1-42 detected within undifferentiated cells 
showed lower but not statistically-significant values compared to controls (Fig. S1, Supporting 
information). 
 
NAC prevents the up-regulation of - and -secretases, as well as the over-production of Aβ1-
42, in SK-N-BE cells challenged with either 27-OH or 24-OH 
Differentiated SK-N-BE cells were incubated in the presence of the strong redox active and 
antioxidant compound NAC, to investigate whether a redox imbalance was also implicated in the 
observed pro-amyloidogenic effect exercised by 27-OH and 24-OH. 
The protective action exerted by NAC was demonstrated to be essentially dependent on this 
thiol compound’s complete prevention of 27-OH- and 24-OH-induced up-regulation of BACE1 
protein levels (Fig. 6A). Consistent with these latter findings was the prevention of 27-OH-induced 
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increase of PS1 intracellular levels observed in differentiated SK-N-BE cells pre-treated with NAC 
(Fig. 6A). 
In this series of experiments, again, challenge of the neuron-like SK-N-BE cells with either 
27-OH or 24-OH induced a marked increase in the steady-state concentration of intracellular Aβ1-42. 
However, the most interesting finding was that the -amyloidogenic effect exerted by the two 
oxysterols on differentiated SK-N-BE cells was completely prevented when cell aliquots were 
incubated for 1 h in the presence of 100 µM NAC, prior to challenge with the cholesterol oxides 
(Fig. 6B). 
 
 
Discussion 
Despite general agreement concerning the significant contribution made by deranged brain 
cholesterol metabolism to the onset and progression of AD, both in the familial form and also in the 
commoner sporadic form, this metabolic impairment has not recently been investigated in depth. 
Systematic studies of this and other structural and metabolic changes in the brain of AD patients, as 
well as conclusive diagnoses, are today only available post-mortem after autoptic inspection; 
furthermore, proper identification and quantification of cholesterol metabolites in human tissues 
require sophisticated instruments (gas chromatography-mass spectrometry, GC-MS) and relatively 
complex methods of tissue preparation and analysis. 
Since the oxidation rate of cholesterol is without doubt crucial for the sterol’s homeostasis in 
the brain, and since excess amounts of cholesterol oxidation products, particularly of oxysterols, 
have been shown to be detrimental to various types of cells and tissues (Poli et al., 2013), it would 
be of primary interest to know whether specific oxysterols do accumulate in AD brains, and if 
possible to discriminate such findings between early and advanced disease stages. 
The data reported here are from a pilot study on a limited number of autopsy samples, of 
brains in which the presence of AD neuropathology has been confirmed by immunohistochemical 
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methods. A net accumulation of both 27-OH and 24-OH was detected in the frontal cortex of all AD 
brains examined, compared to autopsy samples of frontal cortex from control brains (Table 1). The 
frontal cortex, as other neocortical regions, is early involved by Aβ deposits in AD, while the 
hippocampus is site of early neurodegeneration and formation of neurofibrillary changes, but 
exhibits consistent Aβ lesions only at later stages (Thal et al., 2002). We then chose to examine the 
frontal cortex, because the study’s main aim was to investigate the relationship between Aβ and 
cholesterol metabolism. 
Of interest, in the brains that we used as controls we excluded the presence of Aβ 
deposition, ruling out the possibility that they represent nondemented elderly subjects with 
significant number of Aβ deposits. Even more interestingly, there was an upward trend of 27-OH 
and 24-OH accumulation with progression of the level of Braak and Braak staging of neurofibrillary 
pathology (Table 1). Although the small number of samples analyzed thus far does not allow any 
definitive conclusions to be drawn, the results of this pilot study appear of sufficient significance to 
support the implication of an altered cholesterol oxidative metabolism in the pathogenesis of 
sporadic AD. 
To our knowledge, only one study has addressed the quantitative measurement of 27-OH 
and 24-OH levels in the brain cortex of AD patients. That study showed a net increase only of 27-
OH in the frontal cortex of AD brains compared to age-matched normal ones, while 24-OH levels 
in AD frontal cortex specimens were reported to be unchanged (Heverin et al., 2004). Those data 
were obtained from a similar number of cases, namely eight AD autopsy samples, and by applying 
virtually the same assay procedure, i.e. isotope dilution mass spectrometry. However, the values 
were one order of magnitude higher than those found in the present study. Levels of 27-OH and 24-
OH in the frontal cortex from normal brains were reported to be in the range of 1-2 and 18-20 
ng/mg tissue, respectively (Heverin et al., 2004), while in our study the corresponding average 
values were 0.1-0.2 ng/mg tissue 27-OH and 2 ng/mg tissue 24-OH (Table 1). 
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Besides providing very useful suggestions for in vitro tests of patho-physiologically relevant 
amounts of brain oxysterols, the oxysterol quantification in brain frontal cortex reported here points 
to an increase of 27-OH and 24-OH in the cortex of AD brain versus normal brains, with a trend 
that appears related to the disease severity. 
With regard to the in vitro investigation of the potential pro--amyloidogenic effect of 27-
OH and 24-OH, the present study differs from previous analogous ones essentially in two ways: the 
cell line employed, and the chosen final concentration of the two oxysterols. Other studies into the 
effect of one or both oxysterols on APP processing used the human neuroblastoma-derived cell line 
SH-SY5Y, except for one study employing human neural cells (HN cells) in primary culture 
(Alexandrov et al., 2005). The latter report was the only one to show a marked induction of APP 
protein by cell challenge with 10 µM 24-OH; the few other data available on the effect of 24-OH on 
APP protein levels (Prasanthi et al., 2009) and -amyloidogenesis (Famer et al., 2007; Prasanthi et 
al., 2009) either found no effect, or even found a protective effect of this oxysterol. Concerning 27-
OH, it has been shown that this oxysterol, at the final concentration of 10 M, significantly reduced 
A peptide production in primary human neurons (Kim et al., 2009) while in other papers, in 27-
OH-treated SH-SY5Y cells, APP processing was found either similar to control values (Famer et 
al., 2007) or significantly enhanced (Prasanthi et al., 2009). SH-SY5Y cells were in any case 
directly challenged with the investigated oxysterols, without prior retinoic acid-driven 
differentiation towards a more neuron-like phenotype. Conversely, in SK-N-BE cells ten days of 10 
µM all-trans-retinoic acid exposure induced evident markers of neuronal differentiation, both 
morphological and biochemical (Melino et al., 1997). In particular, already within 7 days of cell 
medium supplementation with all-trans-retinoic acid, neuroblastoma-derived cells show a neuron-
like phenotype (Chambaut-Guérin et al., 1995), as confirmed by increased expression levels of the 
specific differentiation markers GAP-43 (Silvagno et al., 2002), NF-200 and NeuN (Redova et al., 
2010). The other peculiarity of the present study is the lower oxysterol final concentration adopted 
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(1 µM) then that used in other studies, which were in the 5-10 µM range. On the basis of the actual 
amounts of 27-OH and 24-OH recovered from normal and AD brains, it may be concluded that the 
1 µM concentration of these oxysterols is much closer to the actual patho-physiological amount. 
Both 27-OH and 24-OH (1 µM) were demonstrated to induce accelerated APP processing 
toward β-amyloidogenesis in differentiated SK-N-BE cells: both oxysterols significantly up-
regulated APP intracellular levels (Fig. 1), and, more importantly, stimulated BACE1 protein levels 
(Fig. 2), the crucial enzyme in Aβ production. Interestingly, while 24-OH was shown to stimulate 
both expression and synthesis of APP and BACE1, the effect of 27-OH on the cellular levels of the 
two proteins appeared to be essentially posttranslational. 
These findings were corroborated by the up-regulation of BACE1 enzymatic activity (Fig. 
5A), and the markedly increased levels of the Aβ1-42 peptide that were consistently detectable within 
differentiated SK-N-BE cells, challenged with either 27-OH and 24-OH (Fig. 5C). Thus, both 
oxysterols definitely stimulated β-amyloidogenesis at least in the experimental system employed, 
despite the fact they showed a parallel ability to up-regulate expression and synthesis of ADAM10 
(α-secretase), although it’s known to be a protective enzyme (Fig. 4A,B). 
In all previous investigations on the pro-amyloidogenic effect of 27-OH and/or 24-OH, only 
undifferentiated neuroblastoma cell lines and relatively higher oxysterol concentrations (5-10 M) 
were used. Here reported comparative measurements of Aβ1-42 synthesis in differentiated and 
undifferentiated SK-N-BE cells, clearly point to 1 M oxysterol amount and differentiated cells as 
the most efficient concentration and the most convenient cell type to adopt for this kind of study. 
Challenge of differentiated cells with either 1 M 27-OH or 1 M 24-OH was, in fact, the only 
experimental condition consistently showing a very strong enhancement of toxic Aβ production 
(Fig. S1, Supporting information). By the way, the findings reported in Fig. S1 (see Supporting 
information) were in agreement with those obtained by Prasanthi et al. (2009) who showed that 5-
10-25 M 27-OH, but not 24-OH, stimulated the synthesis of the toxic Aβ peptide in 
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undifferentiated human neuroblastoma cells (SH-SY5Y). Very recently, a markedly decreased 
synthesis of Aβ1-40 and a moderate reduction in the synthesis of Aβ1-42 were observed in 
undifferentiated SH-SY5Y incubated 24 h in the presence of 24-OH (1-10 µM) (Urano et al., 2013). 
All other reports only focused on specific aspects of the modulation of the amyloidogenic pathway 
by 27-OH and/or 24-OH without quantifying the levels of the toxic peptide. 
Indeed, 1 M 27-OH/24-OH appears to be the closest concentration to that found in human 
AD brain (see above, Results section); moreover, using differentiated neuroblastoma cell lines is a 
more convenient experimental model than employing undifferentiated cells of “neural” origin, since 
cell differentiation with all-trans-retinoic acid allows the re-expression of many morphologic and 
biochemical features that make cells quite similar to normal “neuronal” cells (Chambaut-Guérin et 
al., 1995; Melino et al., 1997; Silvagno et al., 2002; Redova et al., 2010). 
Even if the conclusions drawn from in vitro studies cannot be directly applicable to neuronal 
cells in vivo, the results obtained appear to be of sufficient significance to suggest their possible in 
vivo relevance. Under specific conditions and concentrations in the brain, not only 27-OH but also 
24-OH might exert detrimental effects on neural and neuronal cells. In this connection, at least 24-
OH was recently shown to potentiate Aβ1-42-induced apoptotic and necrotic death in differentiated 
SK-N-BE and NT-2 neuron-like cells (Gamba et al., 2011) as well as in human dental pulp-derived 
cells showing a neuron-like phenotype (Testa et al., 2012). 
Finally, with regard to the observed complete inhibition of 27-OH- and 24-OH-dependent 
stimulation of BACE1 level and A production in SK-N-BE cells pre-treated with NAC (Fig. 6), a 
possible involvement of oxysterol-mediated redox impairment is hypothesized. On the one hand, 
both expression and levels of BACE1 have been shown to be up-regulated by oxidative stress 
conditions and lipid peroxidation end-products (Tamagno et al., 2003; Huang et al., 2013) and the 
pro-amyloidogenic processing has been found to be inhibited by a number of polyphenolic 
compounds, all provided with strong antioxidant effects (Shimmyo et al., 2008; Williams & 
Spencer, 2012). Moreover, a growing bulk of experimental evidence points to oxysterols as 
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potential inducers of reactive oxygen species (ROS), either by inducing different isoforms of the 
NADPH oxidase, or by deranging the mitochondrial membrane potential (Pedruzzi et al., 2004; 
Biasi et al., 2009; Gamba et al., 2011; Biasi et al., 2013). 
In conclusion, we have found a low micromolar amount of 24-OH and 27-OH, the two main 
oxysterols with potential neurodegenerative action, in the frontal cortex of post-mortem samples 
from normal brains. This concentration was consistently increased in AD brain. Even if the 
mechanism/s underlying the observed accumulation of these oxysterols in AD brain are not yet 
completely understood, a redox state impairment in the brain developing the disease seems to play a 
central role. Oxidative stress is, indeed, recognized as being involved in the onset of AD (Sayre el 
al., 2001; Texel & Mattson, 2011; Rodrigues et al., 2012); in this connection, we found that 
neuronal cell pre-treatment with the redox active molecule NAC prevents 27-OH- and 24-OH-
induced β-amyloidogenesis. The strong inhibitory effect displayed by NAC against BACE1 
increase and A accumulation in human neuron-like cells provides a mechanistic rationale for new 
preventative and therapeutic strategies of sporadic AD. The therapeutic efficacy of NAC is, in fact, 
presently under investigation in a number of psychiatric disorders characterized by oxidative stress, 
including schizophrenia, nicotine and cocaine addiction, and obsessive-compulsive syndrome (Dean 
et al., 2011). Moreover, the treatment of AD patients with certain nutraceutical formulations 
containing NAC exerts a significant cognitive improvement in comparison with placebo. A number 
of clinical trials are now in progress to confirm the protective action of NAC (Berk et al., 2013). 
Our findings link an impaired cholesterol oxidative metabolism to an excessive -
amyloidogenesis and point to NAC as an efficient inhibitor of oxysterols-induced A toxic peptide 
accumulation in the brain. 
 
Experimental procedures 
Cell culture, differentiation and treatments 
17 
 
SK-N-BE neuroblastoma cells were maintained in RPMI (Roswell Park Memorial Institute) 1640 
medium containing 2 mM glutamine and supplemented with 10% fetal bovine serum, 1% non-
essential aminoacids and 1% antibiotic mixture (penicillin-streptomycin-amphotericin) in a 
humidified atmosphere at 37°C with 5% CO2. For differentiation, 2x10
6 
cells were plated in 75 cm
2
 
culture flasks (Costar, Lowell, MA, USA) and exposed to 10 µM all-trans-retinoic acid for 10 days. 
The growth medium was changed thrice weekly. 
Cells were treated with 1 μM 27-OH or with 1 µM 24-OH (Steraloids, Newport, RI, USA), 
both dissolved in ethanol. In some experiments, cells were pre-treated with 100 μM NAC 1 h before 
the oxysterol treatments. Incubation times for all experiments are reported in the Results section and 
Figure legends. 
In an additional set of experiments, the oxysterol concentration used in this study (1 µM) 
was compared to those present in the relevant literature (5 µM and 10 µM) with regard to their 
effect on Aβ1–42 production in both differentiated and undifferentiated SK-N-BE cells. 
 
Neuropathological characterization of AD and control brains 
Brains were obtained from hospitalized patients at the Institute of Neurology Carlo Besta (Milan, 
Italy). In the brains included into the present study, routine neuropathological examination excluded 
relevant lesions such as tumors, significant vascular disease/stroke, inflammation, while revealed 
the presence of significant AD pathology, in terms of Aβ deposits and neurofibrillary changes. 
The two AD hallmarks were searched by immunohistochemistry using antibodies against Aβ 
(4G8 1:4000, Signet Laboratories, Dedham, MA) after formic acid pre-treatment for 30 min and 
phospho-tau (AT8 1:300, Innogenetics, Ghent, Belgium). The immunoreaction was visualized using 
the EnVision Plus/Horseradish Peroxidase system (DakoCytomation) and 3-3’-diaminobenzidine as 
chromogen. 
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The brains were classified based on Braak and Braak staging system of neurofibrillary 
pathology (Braak & Braak, 1991). Six brains resulted at stage 1 or 2 (age at death from 72 to 86 
years), and 6 brains were at stage 4 to 6 (age at death from 68 to 82 years).  
In the four brains used as controls (age at death from 25 to 71 years) the presence of Aβ and 
tau pathology was excluded. 
 
Oxysterol quantification in brain tissue 
All autoptic samples were obtained between 24 and 36 h after death, and frontal cortex aliquots for 
oxysterols’ measurements were immediately washed with phosphate-buffered saline (PBS) to 
remove contaminating blood and stored at -80°C. Oxysterols were measured by isotope dilution 
mass spectrometry essentially as previously described (Iuliano et al., 2003) with the exception that 
25,26,26,26,27,27-hexadeuterocholest-5-ene-3ß,27-diol and 25,26,26,26,27,27,27-
heptadeuterocholest-5-ene-3ß,24-diol (Avanti PolarLipids, Alabaster, AL, USA) were used as 
internal standards, and the solid phase extraction (SPE) step was repeated twice to eliminate 
cholesterol. The mass spectrometer was set to the selected ion monitoring mode; the ions used for 
analysis were as follows: [
2
H6 ]-27-hydroxycholesterol 463 m/z, [
2
H6 ]-24-hydroxycholesterol 463 
m/z, 27-hydroxycholesterol 456 m/z, and 24-hydroxycholesterol 456 m/z (Avanti PolarLipids). 
Quantification of oxysterols was made by the internal standard ratio method. 
 
Preparation of cell lysates 
Confluent differentiated cells were treated under the appropriate experimental conditions and placed 
immediately on ice-cold PBS. Whole-cell extracts were prepared in ice-cold lysing buffer [1 ml of 
PBS was fortified with 10 μL Triton X 100, 10 µL SDS 10%, 5 μL dithiotreitol (DTT) 1M, 6 µL 
phenylmethylsulfonylfluoride 0.1%, and 10 μL aprotinin) for 20 min. The lysates were cleared by 
centrifugation at 14,000 g for 25 min. The protein concentration was measured following 
Bradford’s method (1976). 
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RNA extraction and cDNA synthesis 
Total RNA was extracted using TRIzol Reagent (Applied Biosystems, Monza, Italy) following the 
manufacturer’s instructions. RNA was dissolved in RNase-free water fortified with RNase 
inhibitors (RNase SUPERase-In; Ambion, Austin, TX, USA). The amount and purity (A260/A280 
ratio) of the extracted RNA were assessed spectrophotometrically. cDNA was synthesized by 
reverse transcription from 2 µg RNA with a commercial kit and random primers (High-Capacity 
cDNA Reverse Transcription Kit; Applied Biosystems) following the manufacturer’s instructions. 
 
Real time RT-PCR 
Singleplex real-time RT-PCR was performed on 30 ng of cDNA using TaqMan Gene Expression 
Assay kits prepared for human APP, BACE1, PS1, ADAM10 and β2-microglobulin, TaqMan Fast 
Universal PCR Master Mix, and 7500 Fast Real-Time PCR System (Applied Biosystems). Negative 
controls did not include cDNA. The oligonucleotide sequences are not revealed by the manufacturer 
because of proprietary interests. The cycling parameters were as follows: 20 s at 95°C for 
AmpErase UNG activation, 3 s at 95°C for AmpliTaq Gold DNA polymerase activation, 40 cycles 
of 3 s at 95°C (melting), and 30 s at 60°C (annealing⁄extension). The fractional cycle number (Ct) at 
which fluorescence passes the threshold in the amplification plot of fluorescence signal versus cycle 
number was determined for each gene considered. The results were then normalized to the 
expression of β2-microglobulin, as housekeeping gene. Relative quantification of target gene 
expression was achieved with a mathematical method proposed by Livak & Schmittgen (2001). 
 
Antibodies and immunoblot analysis 
The following antibodies were used: polyclonal antibody specific for 22 amino acids of the c-
terminus of APP (Zymed Laboratories, Inc. San Francisco, CA, USA); polyclonal BACE1 antibody 
(Millipore, Temecula, CA, USA); polyclonal CTF-PS1 antibody (Cell Signaling Technology, 
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Beverly, MA, USA); polyclonal ADAM10 antibody (Santa Cruz, Biotechnology Inc., Santa Cruz, 
CA, USA). 
Total lysates were subjected to sodium dodecylsulfate-polyacrilamide gel electrophoresis on 
9.3% acrylamide gels, using the mini-PROTEAN II electrophoresis cell (BioRad, Hercules, CA, 
USA). Proteins were transferred onto nitrocellulose membranes (Hybond-C extra GeHealthcare, 
Arlington Heights, IL, USA). Non-specific binding was blocked with 5% non-fat dry milk in 50 
mM Tris-HCl, pH 7.4, containing 200 mM NaCl and 0.5 mM Tween-20 (Tris buffered saline 
Tween). The blots were incubated with various different primary antibodies, followed by incubation 
with peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulins in Tris-buffered saline 
Tween containing 2% non-fat dry milk. Reactions were developed with an enhanced 
chemiluminescence system following to the manufacturer’s protocol (Ge Healthcare Biotech Italia, 
Cologno Monzese, Italy). 
 
Evaluation of Aβ1–42 production by ELISA 
After cell treatment, whole-cell extracts were prepared in ice-cold lysing buffer (1 mL PBS was 
fortified with 10 mL TritonX-100, 10 mL SDS 10%, 5 mL DTT 1M, 6 mL PMSF 0.1%, and 10 mL 
aprotinin) for 30 min and sonicated for 1 min. The lysates were then cleared by centrifugation at 
17,860 g for 15 min. The protein concentration was measured following Bradford’s method (1976). 
Aβ1-42 levels were quantified using the Human/Rat βAmyloid (42) ELISA Kit (Wako Chemicals 
GmbH, Neuss, Germany) following the manufacturer’s instructions. 
 
Determination of -secretase (BACE1) activity 
The activity of BACE1 was determined using a commercially-available secretase kit (Calbiochem, 
Merck, Darmstadt, Germany), following the manufacturer’s protocol. Cells were lysed in cold 1x 
Extraction buffer (ready for use in the kit) to yield a final protein concentration of mg/mL. The 
method is based on the secretase-dependent cleavage of a secretase-specific peptide conjugated to 
21 
 
the fluorescent reporter molecules EDANS and DABCYL, which results in the release of a 
fluorescent signal that can be detected on a fluorescence microplate reader (excitation wavelength 
355 nm, and emission wavelength 510 nm). The secretase enzymatic activity is proportional to the 
fluorimetric reaction. Data were expressed as percentage change versus activity of control cells. 
 
Determination of γ-secretase activity 
Cells were lysed in a hypotonic buffer containing 10 mM Tris-HCl, pH 7.4, 1 mM EGTA and 1 
mM EDTA. To extract the dissolved proteins, samples were centrifuged at 12,000 g for 20 min and 
the supernatants were collected. To measure the enzymatic activity, 20 μg proteins were incubated 
with 20 µM of a fluorescent conjugated peptide substrate (NMA-GGVVIATVK (DPN)-DRDRDR-
NH2) (Calbiochem, Merck, Darmstadt, Germany) at 37°C for 2 h. The degree of substrate cleavage 
was measured by the emitted fluorescence, using a reader (Perkin-Elmer LS-55) with an excitation 
wavelength of 355 nm and an emission wavelength of 440 nm. Data were expressed as percentage 
change versus activity of control cells. 
 
Statistical analysis 
All values are expressed as means ± standard deviation (SD). Data were assessed using one-way 
ANOVA with Bonferroni’s post-test for multiple comparisons. Differences at P < 0.05 were 
considered statistically significant. Calculations were made with GRAPHPAD INSTAT3 software 
(GraphPad Software Inc., San Diego, CA, USA). 
 
Acknowledgments 
The authors thank the Italian Ministry of University (Prin 2009), the CRT Foundation, Turin, and 
the University of Turin, Italy, for supporting this work. 
 
References 
22 
 
Alexandrov P, Cui JG, Zhao Y, Lukiw WJ (2005) 24S-hydroxycholesterol induces inflammatory 
gene expression in primary human neural cells. Neuroreport. 16, 909-913. 
Berk M, Malhi GS, Gray LJ, Dean OM (2013) The promise of N-acetylcysteine in neuropsychiatry. 
Trends Pharmacol. Sci. 34, 167-177. 
Biasi F, Mascia C, Astegiano M, Chiarpotto E, Nano M, Vizio B, Leonarduzzi G, Poli G (2009) 
Pro-oxidant and proapoptotic effects of cholesterol oxidation products on human colonic epithelial 
cells: a potential mechanism of inflammatory bowel disease progression. Free Radic. Biol. Med. 47, 
1731-1741. 
Biasi F, Guina T, Maina M, Cabboi B, Deiana M, Tuberoso CI, Calfapietra S, Chiarpotto E, Sottero 
B, Gamba P, Gargiulo S, Brunetto V, Testa G, Dessì MA, Poli G, Leonarduzzi G (2013) Phenolic 
compounds present in Sardinian wine extracts protect against the production of inflammatory 
cytokines induced by oxysterols in CaCo-2 human enterocyte-like cells. Biochem. Pharmacol. 86, 
138-145. 
Björkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler 
Thromb. Vasc. Biol. 24, 806-815. 
Björkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative 
diseases. Mol. Aspects Med. 30, 171-179. 
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol. 82, 239-259. 
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254. 
Brown AJ, Jessup W (2009) Oxysterols: Sources, cellular storage and metabolism, and new insights 
into their roles in cholesterol homeostasis. Mol. Aspects Med. 30, 111-122. 
Brown J 3rd, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley 
J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B (2004) Differential expression 
of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 279, 34674-34681. 
23 
 
Chambaut-Guérin AM, Martinez MC, Hamimi C, Gauthereau X, Nunez J (1995) Tumor necrosis 
factor receptors in neuroblastoma SKNBE cells and their regulation by retinoic acid. J. Neurochem. 
65, 537-544. 
Dean O, Giorlando F, Berk M (2011) N-acetylcysteine in psychiatry: current therapeutic evidence 
and potential mechanisms of action. J. Psychiatry Neurosci. 36, 78-86. 
Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination of cholesterol oxidation 
products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225, 73-80. 
Ehrlich D, Humpel C (2012) Chronic vascular risk factors (cholesterol, homocysteine, ethanol) 
impair spatial memory, decline cholinergic neurons and induce blood-brain barrier leakage in rats in 
vivo. J. Neurol. Sci. 322, 92-95. 
Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR (2004) Cholesterol and APOE 
genotype interact to influence Alzheimer disease progression. Neurology. 62, 1869-1871. 
Famer D, Meaney S, Mousavi M, Nordberg A, Björkhem I, Crisby M (2007) Regulation of alpha- 
and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-
secretase pathway. Biochem. Biophys. Res. Commun. 359, 46-50. 
Gamba P, Leonarduzzi G, Tamagno E, Guglielmotto M, Testa G, Sottero B, Gargiulo S, Biasi F, 
Mauro A, Viña J, Poli G (2011) Interaction between 24-hydroxycholesterol, oxidative stress, and 
amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging 
Cell 10, 403-417. 
Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G (2012) The link between altered 
cholesterol metabolism and Alzheimer's disease. Ann. N. Y. Acad. Sci. 1259, 54-64. 
Ghribi O (2008) Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in 
rabbit brain, hippocampal organotypic slices, and skeletal muscle. J. Alzheimers Dis. 15, 673-684. 
Ghribi O, Larsen B, Schrag M, Herman MM (2006) High cholesterol content in neurons increases 
BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 200, 460-
467. 
24 
 
Heverin M, Bogdanovic N, Lütjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad 
B, Björkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of 
patients with Alzheimer's disease. J. Lipid Res. 45, 186-193. 
Huang YJ, Jin MH, Pi RB, Zhang JJ, Ouyang Y, Chao XJ, Chen MH, Liu PQ, Yu JC, Ramassamy 
C, Dou J, Chen XH, Jiang YM, Qin J (2013) Acrolein induces Alzheimer's disease-like pathologies 
in vitro and in vivo. Toxicol. Lett. 217, 184-191. 
Iuliano L (2011) Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem. Phys. 
Lipids 164, 457-468. 
Iuliano L, Micheletta F, Natoli S, GinanniCorradini S, Iappelli M, Elisei W, Giovannelli L, Violi F, 
Diczfalusy U (2003) Measurement of oxysterols and alpha-tocopherol in plasma and tissue samples 
as indices of oxidant stress status. Anal. Biochem. 312, 217-223. 
Kim WS, Chan SL, Hill AF, Guillemin GJ, Garner B (2009) Impact of 27-hydroxycholesterol on 
amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human 
neurons. J. Alzheimers Dis. 16, 121-131. 
Leonarduzzi G, Sottero B, Poli G (2002) Oxidized products of cholesterol: dietary and metabolic 
origin, and proatherosclerotic effects. J. Nutr. Biochem. 13, 700-710. 
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408. 
Melino G, Draoui M, Bellincampi L, Bernassola F, Bernardini S, Piacentini M, Reichert U, Cohen 
P (1997) Retinoic acid receptors alpha and gamma mediate the induction of "tissue" 
transglutaminase activity and apoptosis in human neuroblastoma cells. Exp. Cell Res. 235, 55-61. 
Pedruzzi E, Guichard C, Ollivier V, Driss F, Fay M, Prunet C, Marie JC, Pouzet C, Samadi M, 
Elbim C, O'dowd Y, Bens M, Vandewalle A, Gougerot-Pocidalo MA, Lizard G, Ogier-Denis E 
(2004) NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress 
and apoptosis in human aortic smooth muscle cells. Mol. Cell Biol. 24, 10703-10717. 
25 
 
Poli G, Sottero B, Gargiulo S, Leonarduzzi G (2009) Cholesterol oxidation products in the vascular 
remodeling due to atherosclerosis. Mol. Aspects Med. 30, 180-189. 
Poli G, Biasi F, Leonarduzzi G (2013) Oxysterols in the pathogenesis of major chronic diseases. 
Redox Biology 1, 125-130. 
Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O (2009). Differential 
effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein 
levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4, 1. 
Redova M, Chlapek P, Loja T, Zitterbart K, Hermanova M, Sterba J, Veselska R (2010) Influence 
of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma 
cell lines. Intern. J. Mol. Med. 25, 271-280. 
Reitz C (2012) Dyslipidemia and dementia: current epidemiology, genetic evidence, and 
mechanisms behind the associations. J. Alzheimers Dis. 30, S127-S145. 
Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, Domenicotti C (2012) 
Cholesterol and Alzheimer's disease: a still poorly understood correlation. IUBMB Life 64, 931-935. 
Rodrigues R, Smith MA, Wang X, Perry G, Lee HG, Zhu X, Petersen RB (2012) Molecular 
neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of 
oxidative stress. Future Neurol. 7, 287-305. 
Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in 
neurodegenerative disease. Curr. Med. Chem. 8, 721-738. 
Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther 
K, Schröder J (2002) Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with 
Alzheimer's disease compared to healthy controls. Neurosci. Lett. 324, 83-85. 
Schweinzer C, Kober A, Lang I, Etschmaier K, Scholler M, Kresse A, Sattler W, Panzenboeck U 
(2011) Processing of endogenous AβPP in blood-brain barrier endothelial cells is modulated by 
liver-X receptor agonists and altered cellular cholesterol homeostasis. J. Alzheimers Dis. 27, 341-
360. 
26 
 
Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H (2008) Epigallocatechin-3-gallate and 
curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. 
Neuroreport. 19, 1329-1333. 
Silvagno F, Guarnieri V, Capizzi A, Pescarmona GP (2002) Synergistic effect of retinoic acid and 
dehydroepiandrosterone on differentiation of human neuroblastoma cells. FEBS Lett. 532, 153-158. 
Sottero B, Gamba P, Gargiulo S, Leonarduzzi G, Poli G (2009) Cholesterol oxidation products and 
disease: an emerging topic of interest in medicinal chemistry. Curr. Med. Chem. 16, 685-705. 
Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Abeta deposition in the human brain and its 
relevance for the development of AD. Neurology. 58, 1791-1800. 
Tamagno E, Guglielmotto M, Bardini P, Santoro G, Davit A, Di Simone D, Danni O, Tabaton M. 
(2003) Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed 
to oxidative stress. Neurobiol. Dis. 14, 291-301. 
Testa G, Gamba P, Di Scipio F, Sprio AE, Salamone P, Gargiulo S, Sottero B, Biasi F, Berta GN, 
Poli G, Leonarduzzi G (2012) Potentiation of amyloid-β peptide neurotoxicity in human dental-pulp 
neuron-like cells by the membrane lipid peroxidation product 4-hydroxynonenal. Free Radic. Biol. 
Med. 53, 1708-1717. 
Texel SJ, Mattson MP (2011) Impaired adaptive cellular responses to oxidative stress and the 
pathogenesis of Alzheimer's disease. Antioxid. Redox Signal. 14, 1519-1534. 
Urano Y, Ochiai S, Noguchi N (2013) Suppression of amyloid-β production by 24S-
hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking. FASEB J. 
27:4305-4315. 
Vejux A, Lizard G (2009) Cytotoxic effects of oxysterols associated with human diseases: induction 
of cell death (apoptosis and⁄or oncosis), oxidative and inflammatory activities, and 
phospholipidosis. Mol. Aspects Med. 30, 153-170. 
Williams RJ, Spencer JP (2012) Flavonoids, cognition, and dementia: actions, mechanisms, and 
potential therapeutic utility for Alzheimer disease. Free Radic. Biol. Med. 52, 35-45. 
27 
 
 
Supporting Information 
 
Additional Supporting Information may be found in the online version of this article at the 
publisher’s web-site. 
Fig. S1 Intracellular Aβ1-42 accumulation modulated by 27-hydroxycholesterol (27-OH) and 24-
hydroxycholesterol (24-OH) in differentiated or undifferentiated SK-N-BE cells. 
 
 
Figure legends 
Fig. 1 Effect of 27-hydroxycholesterol (27-OH) and 24-hydroxycholesterol (24-OH) on the 
expression and synthesis of the amyloid precursor protein (APP). (A) Gene expression was 
quantified by real-time RT-PCR in differentiated SK-N-BE cells treated for times up to 12 h with 1 
µM 27-OH or 24-OH. Untreated cells were taken as control. Data, normalized to β2-microglobulin, 
are expressed as mean values ± SD of four different experiments. **P<0.01, and ***P<0.001 vs. 
control group. (B) APP protein levels were analyzed by Western Blotting in differentiated SK-N-
BE cells treated up to 48 h with 1 µM 27-OH or 24-OH. Untreated cells were taken as control. APP 
densitometric measurements were normalized against the corresponding  actin levels. The 
experiments were conducted in triplicate. *P<0.05, and **P<0.01 vs. control group. 
 
Fig. 2 Effect of 27-hydroxycholesterol (27-OH) and 24-hydroxycholesterol (24-OH) on the 
expression and synthesis of β-secretase (BACE1). (A) Gene expression was quantified by real-time 
RT-PCR in differentiated SK-N-BE cells treated for times up to 12 h with 1 µM 27-OH or 24-OH. 
Untreated cells were taken as control. Data, normalized to β2-microglobulin, are expressed as mean 
values ± SD of four different experiments. *P<0.05, and ***P<0.001 vs. control group. (B) BACE1 
protein levels were analyzed by Western Blotting in SK-N-BE cells treated up to 48 h with 1 µM 
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27-OH or 24-OH. Untreated cells were taken as control. BACE1 densitometric measurements were 
normalized against the corresponding  actin levels. The experiments were conducted in triplicate. 
**P<0.01 vs. control group. 
 
Fig. 3 Effect of 27-hydroxycholesterol (27-OH) and 24-hydroxycholesterol (24-OH) on the 
expression and synthesis of the -secretase subunity presenilin 1 (PS1). (A) Gene expression was 
quantified by real-time RT-PCR in SK-N-BE cells treated for times up to 12 h with 1 µM 27-OH or 
24-OH. Untreated cells were taken as control. Data, normalized to β2-microglobulin, are expressed 
as mean values ± SD of four different experiments. *P<0.05 vs. control group. (B) The C-terminal 
fragment (CTF) of PS1 (CTF-PS1) levels were analyzed by Western Blotting in SK-N-BE cells 
treated up to 48 h with 1 µM 27-OH or 24-OH. Untreated cells were taken as control. CTF-PS1 
densitometric measurements were normalized against the corresponding  actin levels. The 
experiments were conducted in triplicate. *P<0.05, and **P<0.01 vs. control group. 
 
Fig. 4  Effect of 27-hydroxycholesterol (27-OH) and 24-hydroxycholesterol (24-OH) on the 
expression and synthesis of α-secretase (ADAM10). (A) Gene expression was quantified by real-
time RT-PCR in differentiated SK-N-BE cells treated for times up to 12 h with 1 µM 27-OH or 24-
OH. Untreated cells were taken as control. Data, normalized to β2-microglobulin, are expressed as 
mean values ± SD of four different experiments. **P<0.01, and ***P<0.001 vs. control group. (B) 
ADAM10 protein levels were analyzed by Western Blotting in SK-N-BE cells treated up to 48 h 
with 1 µM 27-OH or 24-OH. Untreated cells were taken as control. ADAM10 densitometric 
measurements were normalized against the corresponding  actin levels. The experiments were 
conducted in triplicate. ***P<0.001 vs. control group. 
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Fig. 5 27-hydroxycholesterol (27-OH) and 24-hydroxycholesterol (24-OH) induce Aβ1-42 
production by up-regulating BACE1 and -secretase enzymatic activities in SK-N-BE cells. 
Differentiated SK-N-BE cells were incubated up to 48 h with 27-OH or 24-OH. Untreated cells 
were used as control. BACE1 activity (A) and γ-secretase activity (B) were measured by 
fluorogenic assay using the secretase-specific substrate conjugated to the fluorescent reporter 
molecules. Data were expressed as percentage change vs. activity of control cells. Data are means ± 
SD of three experiments. *P<0.05 vs. control group. (C) Differentiated SK-N-BE cells were 
incubated for 24 h with 27-OH or 24-OH. Untreated cells were used as control. Aβ1-42 intracellular 
concentration was quantified by enzyme-linked immunoassay (ELISA). Data are means ± SD of 
three experiments. ***P<0.001 vs. control group. 
 
Fig. 6 Up-regulation of BACE1 and -secretase and Aβ1-42  over-production are prevented by cell 
pre-treatment with N-acetyl cysteine (NAC). Differentiated SK-N-BE cells were incubated for 24 h 
with 27-hydroxycholesterol (27-OH) or 24-hydroxycholesterol (24-OH). Some cell aliquots were 
also pre-incubated for 1 h with 100 µM NAC. Untreated cells were used as control. (A) The C-
terminal fragment (CTF) of PS1 (CTF-PS1) and BACE1 protein levels were analyzed by Western 
Blotting. CTF-PS1 and BACE1 densitometric measurements were normalized against the 
corresponding β actin levels. The experiments were conducted in triplicate. *P<0.05, and **P<0.01 
vs. control group; #P<0.05, and ##P<0.01 vs. oxysterol groups. (B) Aβ1-42 intracellular 
concentration was quantified by enzyme-linked immunoassay (ELISA). Histograms represent the 
mean values ± SD of three experiments. ***P<0.001 vs. control group, and 
###
P<0.001 vs. 27-OH 
or 24-OH. 
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Fig. S1 Intracellular Aβ1-42 accumulation modulated by 27-hydroxycholesterol (27-OH) and 24-
hydroxycholesterol (24-OH) in differentiated or undifferentiated SK-N-BE cells. SK-N-BE cells, 
differentiated or not, were incubated for 24 h with different concentrations of 27-OH or 24-OH (1, 5 
or 10 M). Untreated cells were used as control. Aβ1-42 concentration was quantified by enzyme-
linked immunoassay (ELISA). Histograms represent the mean values ± SD of three experiments. 
***P<0.001 and **P<0.01 vs. control group. 
 
 
 
 
 
Table 1 Quantification of 27-hydroxycholesterol (27-OH) and 24-
hydroxycholesterol (24-OH) in autopsy samples of frontal cortex from AD brains 
 
 
 
 
 
 
 
Early AD (Braak and Braak stages 1, 2); late AD (Braak and Braak stages 4, 6). 
Control brain samples: n=4; early AD samples: n=6; late AD samples: n=6. 
*
P<0.05, and 
**
P<0.01 vs. control; 
#
P<0.05 vs. early AD. 
 
 
 
 
 
 
27-OH (ng/mg) 24-OH (ng/mg) 
Control 
Early AD 
Late AD 
Total AD 
0.2 ± 0.02 
0.4 ± 0.10 
0.9 ± 0.32 
**,#
 
0.7 ± 0.39 
*
 
2.5 ± 0.14 
3.3 ± 0.04 
7.6 ± 2.86 
*,#
 
5.6 ± 2.8 
*
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